A Patient Registry Study for Patients Treated With Voretigene Neparvovec in US

NCT03597399 · clinicaltrials.gov ↗

COMPLETED

Status

87

Enrollment

INDUSTRY

Sponsor class

Conditions

Confirmed Biallelic RPE65 Mutation-associated Retinal Dystrophy

Interventions

BIOLOGICAL: AAV2-hRPE65v2,voretigene neparvovec-rzyl

Sponsor

Spark Therapeutics, Inc.